Thank you, good And everyone. morning, Michel.
readouts We next our our Illustrating are efforts the we pipeline very in momentum months. with mid expanding to late-stage in neuroscience to the over our pleased immunology. forward with progress XX and look in XX portfolio, the industry-leading
mentioned, are our franchise continue neuromuscular strengthening disorders. MS to Michel As our and top priorities in
we priorities areas. Beyond emphasis are our emerging and the these core refining within
based Therapeutics, we can immunology a core we our area. see the as view this Moreover, potential area. end expertise recognizing we consider the that ophthalmology opportunities growth of an of be in now To long-standing growth Nightstar now acquisition following our existing and to on assets emerging
if begin neuromuscular franchises. the let Diving our secure annual consortium we me meetings the with of American quarter at At in, of and and fumarate approved we study, EVOLVE Academy with long-term and second single-arm efficacy ongoing the evaluating multiple in relapsing-remitting leadership to diroximel marketed the new sclerosis the scientific as to be Neurology MS advances in made VUMERITY open-label safety of in from interim an FDA centers, MS. data MS-X, X-year patients III by Phase presented the
patients was when to with patients. a XX% rate one showed treatment over reduction baseline, annualized year Interim relapse the diroximel an newly results that diagnosed in with XXX reduction compared fumarate associated MS in XX% in with
patients. in by the XX% by baseline number diagnosed diroximel reduced lesions in XX% mean compared gadolinium-enhancing newly The was of with treated patients to in total fumarate and population
weeks. we year in in to EVOLVE versus fumarate adverse is study. now events This discontinuation and study X.X%. TECFIDERA gastrointestinal MS-X GI the completion leading is evaluated of one diroximel tolerability ongoing rate of results Over the been was coming near expect
subject first Phase also that or inhibitor announce a Bruton's the am I kinase to tyrosine we I in of of have selective dosed potent BIIBXXX, the highly pleased small molecule and study BTK.
contribute has pathogenesis a BIIBXXX we best-in-class of myeloid B non-covalent non-receptor innovator selectivity BTK tyrosine and in to its a signaling with regulates MS. hypothesized and together and cells which the development BTK of kinase that potentially to Notably of profile. potency high believe cells are is that is
and This of placebo-controlled safety, in pharmacokinetics the pharmacodynamics BIIBXXX adults. dose study will single evaluate and multiple tolerability, healthy ascending
NURTURE Neurology, Cure presented and our Conference in SMA. the data interim presymptomatic the European SMA Academy disorders. in SPINRAZA Xth At Turning Annual to the infants of progress of study we new of with from Congress neuromuscular the
analysis, study XX this highlighted to ongoing remarkable once of again efficacy open-label the up of profile including SPINRAZA. Now months
study XX were and or treated tracheostomy Specifically, assistance. in patients presymptomatic none permanent or SMA SPINRAZA this XXX% sitting of alive, the XX% ventilation. independently with were required with independently XXX% were with walking
of SMNX score patients patients of XX.X XX of XX. score XX INTEND In the the of visit, XX.X with achieved At score measure a out last and approaching were achieved mean function. maximum two three of out CHOP a on motor mean patients with copies of SMNX addition,
motor also of these patients of showed overwhelming that timeframe majority had data these Importantly, achieved milestones within the the development. normal
the durable SMA years a remain will range unsurpassed foundation profile its broad of efficacy with longer-term real-world SMA for of action a of care believe reversible targeted of the safety well SPINRAZA come. patients, and robust, mechanism SPINRAZA we across Given established experience, to in
of potential nervous antisense therapies transformative Moreover, to system. the alter that oligonucleotide we believe diseases of course the dramatically of SPINRAZA demonstrates the
are depth such We by neurological ASO genetic our underpinnings as range excited the of diseases ALS. targeting of a of the pipeline
genetic during of ALS modulation target linked described we we is forms webcast, our as Specifically, are of to recent ALS genetic disease. targeting causally where
oligonucleotide For ALS. antisense VALOR and SODX instance, this we study of believe Phase designed for has the ALS. devastating an advance to to of tofersen, We registration that degrade to support form study the X continue potential this SODX genetic mRNA
We study finalized XXX X which design, or Phase placebo. XX have treated milligram tofersen includes patients now the with
this expect three of XX XX on four a this stage every followed the loading days, week in final from XX three receive doses study, will we Based the course first maintenance doses readout the weeks over XXXX. by weeks. study patients Over study design, –
We the ALS. expansions expected study most of in are study targeting also also CXORFXX, in antisense genetic X repeat oligonucleotide from common hexanucleotide to the of an Data advance this cause BIIBXXX, XXXX. continue Phase
larger BIIBXXX ALS that sporadic the I drug the scientifically for study novel this last to of Further, X To the end, pursuing first was we pleased Phase dosed sporadic month. driven announce opportunity patient are ALS. targets in am in for
cytoplasm. is of small XPOX, export nucleus many exportin inhibitor proteins nuclear the to X that molecule a a BIIBXXX from the of transport mediates cell factor or the
clinical the ALS. aim nucleoprotein export to of test the of With the reducing prevent inclusions formation that and cytoplasmic thereby BIIBXXX, neuronal progression may slow sporadic hypothesis we
We movement in gosuranemab supranuclear year. or expected could data regulatory the filing. In positive in a from anti-tau is palsy believe potentially BIIBXXX study X with of antibody this disorders, data Phase the second our the support study half fully this progressive enrolled of
disorder completed enrollment Phase the extracellular monoclonal is X disease. prevalence Parkinson's of of disease a patients to second the available with antibody targeting million three Also this the for we across Parkinson's neurodegenerative alpha-synuclein common the BIIBXXX, slow study GX no its and progression. quarter inexorable of treatment approximately
genetic and neurons can pathogenesis. role Parkinson’s dopaminergic in Parkinson’s of nigro-striatal of shows hallmark disease Aggregation alpha-synuclein pathologies alpha-synuclein a of from familial disease degeneration that data misfolded disease represents and play causal Parkinson’s
placebo-controlled year, the of next neuro this of as one well half density. to will from study. imaging-based data receive include data a of dopamine second year This as we expect safety the In assessment transporter striatal period
Eisai, advance antisense X Alzheimer’s And we BIIBXXX, in oligonucleotide and dementia, study to partner, the the early two this for up continued end programs by the Elenbecestat, Beyond Parkinson’s disease Phase the patient in clinic X collaboration into for BANXXXX the expect Phase quarter advance and to dosed Alzheimer's year. first also our for early Alzheimer's disease. new the disease disease study for of of
collaboration currently X, Phase in gosuranemab Phase In advance therapeutics X, parallel, Ionis tau-directed to anti-tau BIIBXXX, oligonucleotide tau being continue antisense mRNA in X, a including Phase and our with developed an we of in antibody Pharmaceuticals. portfolio in BIIBXXX, distinct targeting
of advancing disease patients. pursuing and we a suite preclinical subsets targets genetically of Further, Alzheimer’s dementia validated programs defined next-generation are for
we treatment BIIBXXX Moving for associated month schizophrenia. cognitive the this Xb impairment indication. to the for track advance BIIBXXX Phase Last fast with neurocognition, to of continue study designation FDA to of granted the
BIIBXXX compelling from has distinct believe data XXXX. expected a first-in-class Xb Phase Data study that early late from this are receptor of studies. number clinical in we is potentiator AMPA a
As view area emerging Biogen our that expertise long-standing for this advantage in-house I immunology as mentioned earlier, an area. takes we in growth
erythematosus, humanized of lupus completed SLE. BDCAX of systemic we quarter binds Phase This antibody BIIBXXX, enrollment or cutaneous X that CLE the and study lupus a erythematosus, for monoclonal or
and plasmacytoid disease published Phase activity of X CLE. to BIIBXXX in decrease BIIBXXX as on cells, Investigation, led As interferon reduced General skin the Clinical infiltrates immune in of recently study lesions, internalization with with the patients as decreased treatment activation, dendritic in pathway well BDCAX SLE cutaneous shown and and
disease GX, treatment bring With this therapy the area end expected a to approximately options the we modifying and year. forward patients Data of aim from a of prevalence high study to this of across are limited new available need. this XXX,XXX potentially by unmet
- collaboration for in treatment. the in to a we pegol, half with Further, in active an standard-of-care Phase with pegylated ligand UCB, patients despite the anti-CDXX SLE initiate fab year with next first plan dapirolizumab X program of
clinical on promising trial. from is data Congress of presented were the This Rheumatology based decision the Xb Interim month. at this results European the Phase of study last
not will our strategically process or To ongoing of this and programs part we balancing although within and decided potential X to our trials Vixotrigine with a we trigeminal to end, Phase X As continue initiation Phase advance of risk of areas. the that preparation initiate opportunity pipeline, activities next we prioritize neuralgia for continue the disease have BIIBXXX in year, year. in
trigeminal X assess to studies potential continue will year. program will next we evaluate Phase the and We our initiation of neuralgia
in and Vixotrigine We in readout continue Phase study to the of neuropathy to advance fiber that small now from study X expect XXXX.
infarction with of In BIIBXXX and X addition, large edema study as patients the cerebral hemispheric in launch as to early we Phase XXXX. for severe the with of treatment prevention continue enroll the potential
We of of ischemic the in stroke next acute year. a also end by Phase TMSXXX readout X expect
genetically our defined patient emphasizing conclude by focus me on recent Therapeutics. in of our rebalance populations Nightstar validated to pipeline risk, Finally, acquisition targets let highlighting
to with are accelerates excited this into the ophthalmology of genetic to talented are of severe acquisition drug deliver join our to We diseases. therapies options. with to treatment for address patients current extremely forces from gene which This no blindness entry retinal serious first-in-class there team developers causes potential suffering
Our rare as there for of for lead delivered is injection to degenerative by NSR-REPX are therapy leads the treatment inevitably targeted an disease sub-retinal choroideremia, AAV-based candidate, current known no which therapies. a blindness, gene drug that BIIBXXX now
associated subretinal rate injection higher vision was maintained trials, alter treatment significantly the of with of a in with X/X Phase potential in and of has meaningful improvement BIIBXXX the the disease. BIIBXXX this a that subset patients, course visual suggesting via to In acuity,
from STAR the We of year. second of X BIIBXXX Phase expect data the trial next in half
BIIBXXX injection. as Like X-linked therapy now pigmentosa subretinal delivered asset NSR-RPGR XLRP. stage second is clinical or by BIIBXXX, BIIBXXX an Our AAV-based gene known retinitis is targeting targeted
increases from half retinal early enrolling as the data is microperimetry. study Data central dose promising Phase second in BIIBXXX expansion dose-escalation X/X study showed of next year. with currently measured including the sensitivity X/X efficacy, of in of signals Phase by expected
and which are medicine These maybe severe larger blindness associated to diseases diseases, of inherited have patients inevitably genetic to been set solutions. alone disability which up in a similar to S. the the U. lead retinal afflict part amendable of estimated that to XXX,XXX
clinical diseases. platform specialty potentially our inherited to newly ophthalmology across to We leading acquired expand leveraging retinal future look the in opportunity forward
pipeline assets, for clinical a our small for new BIIBXXX for As molecule quarter, and BTK to pigmentosa, Nightstar inhibitor Michel inhibitor X-linked MS, XPOX our mentioned, small choroideremia, for we sporadic this BIIBXXX, a molecule added including ALS. programs four BIIBXXX retinitis BIIBXXX,
we programs And have advance we expand half two clinic additional up added total, past the X.X in we year, new over disease. programs have years this to of to including to antisense for pipeline. XX the clinical second the In into continued as our programs up to oligonucleotide three expect Parkinson’s
As lens, later early our biomarkers deploying risk asymmetric mitigate clinical been and to we by genetics, strategic programs our stage seeking neuroscience. we by stage in prioritizing and expertise targets validated capabilities assets, leveraging that in human continue will widen have
III neuroscience and poised we believe months readouts mid neuromuscular readout MS BIIBXXX the followed stage into emerging for depth XX in our science franchises head-to-head next to of areas. portfolio core build their readouts Phase XX disorders over our reinforce for II including we data late the to and With X the are and Phase VUMERITY, in
Above of all, medicines neurological living developing patients our goal diseases. focused from devastating we transformative on remain with
Jeff. to call I will now pass the
